StockInvest_us Posted - 2 days ago

Signal alert: $TBPH - Possible Runner https://stockinvest.us/l/bF19xIdAcO

Aigner_Andreas Posted - 04/30/24

TD BUY $TBPH at 8.44, Supp 8.44 Resis 9.92 R18 HiLo 7% T1Y 11 hold 2.7 DIV N/A #Theravance #stocks #trading #finance #market

Stock_Titan Posted - 04/29/24

$TBPH Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 https://www.stocktitan.net/news/TBPH/theravance-biopharma-to-report-first-quarter-2024-financial-results-6fe62gbew5m4.html

Stock_Titan Posted - 04/10/24

$TBPH Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 https://www.stocktitan.net/news/TBPH/theravance-biopharma-inc-to-host-virtual-key-opinion-leader-kol-zlgyyg6o92l1.html

Aigner_Andreas Posted - 02/28/24

TD SELL $TBPH at 9.69, Supp 8.22 Resis 9.69 R18 HiLo 40% T1Y 11 hold 2.7 DIV N/A #Theravance #stocks #trading #finance #market

epsguid Posted - 02/26/24

$TBPH reported a loss of $0.17, consensus was ($0.15) via @eWhispers #epsmiss http://eps.sh/d/tbph

Ninja_Tradez Posted - 02/26/24

$SSKN $NRXP $IOBT $TBPH Never Miss any alert 🚨Check Discord Link 🔗 on bio

Stock_Titan Posted - 02/26/24

$TBPH Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update https://www.stocktitan.net/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2023-bu2w6bo7hyof.html

insiderbuyingselling Posted - 02/22/24

$TBPH new insider selling: 1254 shares. http://insiderbuyingselling.com/?t=TBPH

Stock_Titan Posted - 02/22/24

$TBPH Theravance Biopharma to Participate in an Upcoming Investor Conference https://www.stocktitan.net/news/TBPH/theravance-biopharma-to-participate-in-an-upcoming-investor-rd592dfgvtfi.html

Stock_Titan Posted - 02/14/24

$TBPH Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 https://www.stocktitan.net/news/TBPH/theravance-biopharma-to-report-fourth-quarter-and-full-year-2023-l5xpu5wfx4ng.html

briefingcom Posted - 01/16/24

Gapping down early premarket: $TBPH -5% $KEN -4.6% $BIDU -4.1% $BA -2% $TTE -2%

cctranscripts Posted - 01/16/24

Other Events https://www.conferencecalltranscripts.org/summary/?id=12867927 $TBPH

risenhoover Posted - 01/16/24

$TBPH / Theravance Biopharma files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 12, 2024 THERAVANCE BIOPHAR https://fintel.io/doc/sec-theravance-biopharma-inc-1583107-8k-2024-january-16-19738-1363?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

StockAutomatePro Posted - 01/11/24

$TBPH Chart analysis points towards a downward stock trajectory. We alerted the SELL signal at $11.14 and we were able to close this one with profit at $9.78 ✅

shortvolumes Posted - 01/07/24

Short sale volume (not short interest) for $TBPH at 2024-01-05 is 37%. http://shortvolumes.com/?t=TBPH via @shortvolumes

tickeron Posted - 01/06/24

Does this make you nervous? $TBPH Stochastic Oscillator left the overbought zone. View odds of downtrend. https://srnk.us/go/4961229

DonCorleone77 Posted - 01/05/24

$TBPH Theravance Biopharma downgraded at Evercore ISI after Yupelri trial failure As previously mentioned, Evercore ISI analyst Liisa Bayko downgraded Theravance Biopharma to In Line from Outperform with a price target of $8, down from $14, after Yupelri failed in a Phase 4 study that was designed to broaden the addressable market. The firm has updated its model to temper its expectations for the expansion of Yupelri based on the PIFR 2 results and also adjust projections for ampreloxetine, the other active asset in Theravance's pipeline, the analyst tells investors.

DonCorleone77 Posted - 01/05/24

$TBPH Theravance Biopharma downgraded to In Line from Outperform at Evercore ISI Evercore ISI downgraded Theravance Biopharma to In Line from Outperform with an $8 price target.

timfris Posted - 01/05/24

$TBPH hold shares here if you want execs to bleed company through pay and options for who knows how long.

OpenOutcrier Posted - 01/05/24

$TBPH (-19.9% pre) Theravance Biopharma (TBPH) Reports Results from the Phase 4 YUPELRI PIFR-2 Study - SI https://ooc.bz/l/21367

swingingtech Posted - 01/05/24

$TBPH https://wallstreetwaves.com/theravance-drops-as-late-stage-trial-for-copd-therapy-yupelri-fails/

DonCorleone77 Posted - 01/05/24

$TBPH Theravance Biopharma reports PIFR-2 study missed primary endpoint Theravance Biopharma announced results from the Phase 4 PIFR-2 study of Yupelri inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist, or LAMA, approved in the U.S. for maintenance treatment of COPD. The PIFR-2 study aimed to demonstrate greater improvement in lung function for Yupelri delivered via standard jet nebulizer compared to Spiriva delivered via a dry powder inhaler in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate, or PIFR. The study did not show a statistically significant difference between Yupelri and Spiriva HandiHaler on the primary endpoint, change from baseline in trough forced expiratory volume in one second at Day 85. Similar lung function improvement was demonstrated in both arms of the study. Yupelri demonstrated safety and tolerability consistent with its profile in previous clinical studies.

swingingtech Posted - 01/05/24

$FC $APLT $TBPH $VYGR https://wallstreetwaves.com/franklin-covey-shares-fall-after-q1-results-joins-theravance-biopharma-voyager-therapeuti

Last10K Posted - 01/05/24

$TBPH just filed with the SEC a Financial Exhibit https://last10k.com/sec-filings/TBPH/0001104659-24-001556.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=TBPH

cctranscripts Posted - 01/05/24

Theravance Biopharma Announces Results From The Phase 4 Yupelri https://www.conferencecalltranscripts.org/summary/?id=12845807 $TBPH

risenhoover Posted - 01/05/24

$TBPH / Theravance Biopharma files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 5, 2024 THERAVANCE BIOPHARM https://fintel.io/doc/sec-theravance-biopharma-inc-1583107-8k-2024-january-05-19727-5077?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

timfris Posted - 01/05/24

$TBPH textbook example of execs screwing shareholders for more personal gain.

Stock_Titan Posted - 01/05/24

$TBPH Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) https://www.stocktitan.net/news/TBPH/theravance-biopharma-announces-results-from-the-phase-4-yupelri-r-pdex3bz6s1vn.html